AveXis (NASDAQ:AVXS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “

A number of other equities analysts also recently commented on AVXS. Chardan Capital reiterated a “buy” rating and issued a $135.00 target price on shares of AveXis in a report on Friday. Canaccord Genuity set a $110.00 target price on shares of AveXis and gave the stock a “hold” rating in a report on Friday. BMO Capital Markets reiterated a “buy” rating on shares of AveXis in a report on Monday. Citigroup boosted their price target on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. Finally, Morgan Stanley set a $120.00 price target on AveXis and gave the stock a “buy” rating in a research note on Friday. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $111.94.

Shares of AveXis (NASDAQ:AVXS) traded up $4.24 during trading on Tuesday, reaching $106.32. 569,300 shares of the company’s stock were exchanged, compared to its average volume of 515,580. The company has a market capitalization of $3,510.00 and a P/E ratio of -19.05. AveXis has a fifty-two week low of $50.56 and a fifty-two week high of $116.15.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the company posted ($0.87) EPS. sell-side analysts forecast that AveXis will post -6.23 EPS for the current fiscal year.

In related news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the sale, the insider now owns 1,841,019 shares in the company, valued at $186,366,353.37. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Andrew F. Knudten sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the sale, the vice president now owns 7,000 shares in the company, valued at approximately $661,360. The disclosure for this sale can be found here. Insiders have sold 52,340 shares of company stock worth $5,318,845 in the last 90 days. Insiders own 18.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio purchased a new stake in AveXis in the third quarter valued at approximately $116,000. Botty Investors LLC purchased a new stake in AveXis in the second quarter valued at approximately $123,000. Quantbot Technologies LP purchased a new stake in AveXis in the first quarter valued at approximately $117,000. Cubist Systematic Strategies LLC boosted its position in AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after buying an additional 1,577 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in AveXis in the third quarter valued at approximately $200,000. Hedge funds and other institutional investors own 92.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/09/avexis-avxs-raised-to-hold-at-zacks-investment-research.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.